Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

Next Previous
Search
Trial Profile

A Phase I Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALLN 346 (Primary)
  • Indications Hyperuricaemia
  • Focus Adverse reactions; First in man
  • Sponsors Allena Pharmaceuticals

    • Most Recent Events

    • 04 Jun 2022 Results from two studies (NCT04236219 and NCT04829435) assessing safety, tolerability and evidence for lack of systemic absorption at various dose levels presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 09 Mar 2021 Status changed from active, no longer recruiting to completed, according to an Allena Pharmaceuticals media release.
    • 30 Nov 2020 Status changed from recruiting to active, no longer recruiting, according to an Allena Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top